The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview

Cyclodextrins (CDs) are cyclic oligosaccharides of natural origin that were discovered more than 100 years ago. The peculiar cone-like conformation of the sugar ring, expressing a lipophilic cavity and a hydrophilic external surface, allows these substances to spontaneously complex poorly soluble compounds in an aqueous environment. For more than 50 years, these substances have found applicability in the pharmaceutical and food industries as solubilizing agents for poorly soluble chemical entities. Nowadays, several research groups all over the world are investigating their potential as active pharmaceutical ingredients (APIs) for the treatment of several illnesses (e.g., hypercholesterolemia, cancer, Niemann-Pick Type C disease). The aim of this review is to briefly retrace cyclodextrins’ legacy as complexing agents and describe the current and future prospects of this class of chemical entities in pharmaceutics as new APIs.

[1]  T. Irie,et al.  Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. , 2013, Molecular genetics and metabolism.

[2]  C. Demigné,et al.  Effect of cyclodextrin on plasma lipids and cholesterol metabolism in the rat. , 1995, Metabolism: clinical and experimental.

[3]  A. Cooper.  Effect of cyclodextrins on the thermal stability of globular proteins , 1992 .

[4]  T. Kiss,et al.  Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: evidence for the role of cholesterol extraction. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  F. Puisieux,et al.  Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives , 1994 .

[6]  Yong Chen,et al.  Effects of cyclodextrins on the structure of LDL and its susceptibility to copper-induced oxidation. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  Adelailson Peixoto,et al.  Computer-assisted coloring and illuminating based on a region-tree structure , 2012, SpringerPlus.

[8]  D. French,et al.  The Molecular Weights of the Schardinger Alpha and Beta Dextrins1 , 1942 .

[9]  Y. L. Loukas,et al.  Kinetic degradation study of insulin complexed with methyl-beta cyclodextrin. Confirmation of complexation with electrospray mass spectrometry and (1)H NMR. , 2002, Journal of pharmaceutical and biomedical analysis.

[10]  F. Camargo,et al.  Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. , 2001, Life sciences.

[11]  T. Higuchi,et al.  Phase solubility techniques , 1965 .

[12]  L. Szente,et al.  Cyclodextrins in Food Technology and Human Nutrition: Benefits and Limitations , 2016, Critical reviews in food science and nutrition.

[13]  V. Wintgens,et al.  Synthesis and characterization of poly(ethylene glycol) based β-cyclodextrin polymers , 2009 .

[14]  F. Pinguet,et al.  Antiproliferative effect of methyl-beta-cyclodextrin in vitro and in human tumour xenografted athymic nude mice. , 1998, British Journal of Cancer.

[15]  F. Veiga,et al.  A LITERATURE REVIEW OF CYCLODEXTRIN INCLUSION COMPLEXES CHARACTERIZATION - PART II: X-RAY DIFFRACTION, INFRARED SPECTROSCOPY AND NUCLEAR MAGNETIC RESONANCE , 2012 .

[16]  D. French,et al.  Studies on the Schardinger dextrins. XI. The isolation of new Schardinger dextrins. , 1961, Biochemical and biophysical research communications.

[17]  Applications of Complexation in the Formulation of Insoluble Compounds , 2008 .

[18]  Mi-Young Lee,et al.  Spectroscopic characterization of ibuprofen/2-hydroxypropyl-β-cyclodextrin inclusion complex , 1998 .

[19]  Cesar A. López,et al.  Molecular Mechanism of Cyclodextrin Mediated Cholesterol Extraction , 2011, PLoS Comput. Biol..

[20]  M. D. di Cagno,et al.  β-CD-dextran polymer for efficient sequestration of cholesterol from phospholipid bilayers: Mechanistic and safe-toxicity investigations. , 2015, International journal of pharmaceutics.

[21]  D. Smith,et al.  Composition and functional properties of cholesterol reduced egg yolk. , 1997, Poultry science.

[22]  Toshiyuki Murai,et al.  The Role of Lipid Rafts in Cancer Cell Adhesion and Migration , 2011, International journal of cell biology.

[23]  M. Garwood,et al.  Hydroxypropylcyclodextrins in parenteral use. II: Effects on transport and disposition of lipids in rabbit and humans. , 1992, Journal of pharmaceutical sciences.

[24]  Thorsteinn Loftsson,et al.  Cyclodextrins as pharmaceutical solubilizers. , 2007, Advanced drug delivery reviews.

[25]  Niket Thakkar,et al.  Depletion with Cyclodextrin Reveals Two Populations of Cholesterol in Model Lipid Membranes. , 2016, Biophysical journal.

[26]  D. Ory,et al.  Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression , 2009, PloS one.

[27]  A. Sikorski,et al.  Membrane rafts as a novel target in cancer therapy. , 2014, Biochimica et biophysica acta.

[28]  M. Beal,et al.  Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease , 2012, The Journal of experimental medicine.

[29]  K. Uekama,et al.  Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. , 1982, Journal of pharmacobio-dynamics.

[30]  Denise M Smith,et al.  Cholesterol Reduction in Liquid Egg Yolk using β‐Cyclodextrin , 1995 .

[31]  K. A. Connors,et al.  The Stability of Cyclodextrin Complexes in Solution. , 1997, Chemical reviews.

[32]  A. Tall,et al.  Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming , 2016, Science Translational Medicine.

[33]  A. Bauer-Brandl,et al.  β-Cyclodextrin-dextran polymers for the solubilization of poorly soluble drugs. , 2014, International journal of pharmaceutics.

[34]  K. A. Connors,et al.  Population characteristics of cyclodextrin complex stabilities in aqueous solution. , 1995, Journal of pharmaceutical sciences.

[35]  K. Higaki,et al.  Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease. , 2015, Biological & pharmaceutical bulletin.

[36]  J. Nishijo,et al.  Interactions of cholesterol with cyclodextrins in aqueous solution. , 2003, Chemical & pharmaceutical bulletin.

[37]  Shivendra V. Singh,et al.  Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma , 2014, Molecular Cancer.

[38]  V. Wintgens,et al.  Facile synthesis of beta-cyclodextrin-dextran polymers by "click" chemistry. , 2010, Biomacromolecules.

[39]  D. Duchěne.  Cyclodextrins and Their Inclusion Complexes , 2011 .

[40]  K. A. Connors,et al.  Aqueous solubility behavior of three cyclodextrins , 1985 .

[41]  Martin Brandl,et al.  Solubilization of ibuprofen with β-cyclodextrin derivatives: energetic and structural studies. , 2011, Journal of pharmaceutical and biomedical analysis.

[42]  Dominique Duchêne,et al.  Cyclodextrins and their pharmaceutical applications. , 2007, International journal of pharmaceutics.

[43]  Wei Xue,et al.  Effect of cyclodextrins on the structure and functions of blood components in vitro , 2015 .

[44]  R. Kariya,et al.  Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin. , 2013, International journal of pharmaceutics.

[45]  A. Bauer-Brandl,et al.  Driving forces and the influence of the buffer composition on the complexation reaction between ibuprofen and HPCD. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  G. Perkins,et al.  Targeting cholesterol with β‐cyclodextrin sensitizes cancer cells for apoptosis , 2015, FEBS letters.

[47]  K. Levental,et al.  Rafting through traffic: Membrane domains in cellular logistics. , 2014, Biochimica et biophysica acta.

[48]  J. Pitha,et al.  Severe hypervitaminosis A in siblings: evidence of variable tolerance to retinol intake. , 1987, The Journal of pediatrics.

[49]  S. Ye,et al.  Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. , 2006, The American journal of pathology.

[50]  S. Maggo,et al.  Neuroprotective effect of hydroxypropyl-&bgr;-cyclodextrin in hypoxia-ischemia , 2012, Neuroreport.

[51]  S. Kimura,et al.  2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent , 2015, PloS one.

[52]  N. Matubayasi,et al.  Origin of non-linearity in phase solubility: solubilisation by cyclodextrin beyond stoichiometric complexation. , 2016, Physical chemistry chemical physics : PCCP.

[53]  Thorsteinn Loftsson,et al.  Self-association and cyclodextrin solubilization of drugs. , 2002, Journal of pharmaceutical sciences.

[54]  Wenjie Zhu,et al.  Effects of Hydroxylpropyl-β-Cyclodextrin on in Vitro Insulin Stability , 2009, International journal of molecular sciences.

[55]  Rosario Oliva,et al.  Cyclodextrin–protein interaction as inhibiting factor against aggregation , 2017, Journal of Thermal Analysis and Calorimetry.

[56]  Bin-bo Jiang,et al.  HP-β-cyclodextrin as an inhibitor of amyloid-β aggregation and toxicity. , 2016, Physical chemistry chemical physics : PCCP.

[57]  Benny Liu,et al.  Systemic administration of 2‐hydroxypropyl‐β‐cyclodextrin to symptomatic Npc1‐deficient mice slows cholesterol sequestration in the major organs and improves liver function , 2014, Clinical and experimental pharmacology & physiology.

[58]  Thorsteinn Loftsson,et al.  Evaluation of cyclodextrin solubilization of drugs. , 2005, International journal of pharmaceutics.

[59]  F. Hirayama,et al.  Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.

[60]  G. Crini,et al.  Review: a history of cyclodextrins. , 2014, Chemical reviews.

[61]  F. Veiga,et al.  A LITERATURE REVIEW OF CYCLODEXTRIN INCLUSION COMPLEXES CHARACTERIZATION - PART III: DIFFERENTIAL SCANNING CALORIMETRY AND THERMOGRAVIMETRY , 2012 .

[62]  M. Buera,et al.  Phase solubility studies and stability of cholesterol/β-cyclodextrin inclusion complexes. , 2011, Journal of the science of food and agriculture.

[63]  S. Galdiero,et al.  Investigating the inclusion properties of aromatic amino acids complexing beta-cyclodextrins in model peptides , 2015, Amino Acids.

[64]  P. Camilleri,et al.  β‐Cyclodextrin interacts with the Alzheimer amyloid β‐A4 peptide , 1994 .

[65]  Sheng-Kai Xing,et al.  Isothermal Titration Calorimetry and Theoretical Studies on Host-guest Interaction of Ibuprofen with α-, β- and γ-Cyclodextrin , 2009 .

[66]  T. Uyar,et al.  Crystalline Cyclodextrin Inclusion Compounds Formed with Aromatic Guests: Guest-Dependent Stoichiometries and Hydration-Sensitive Crystal Structures , 2006 .

[67]  H. Arima,et al.  Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann–Pick Type C disease , 2014, Molecular genetics and metabolism reports.

[68]  T. Higashi,et al.  Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent , 2013, Scientific Reports.

[69]  J. Seelig,et al.  Calorimetric measurement of phospholipid interaction with methyl-beta-cyclodextrin. , 2004, Biochemistry.

[70]  J. Danielsson,et al.  Two-Site Binding of β-Cyclodextrin to the Alzheimer Aβ(1-40) Peptide Measured with Combined PFG-NMR Diffusion and Induced Chemical Shifts , 2004 .

[71]  R. Gniadecki.  Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. , 2004, Biochemical and biophysical research communications.